$1.170
-0.029 (-2.50%)收盤時
BCLI 同業比較
In the context of the broader market, BCLI competes directly with industry leaders such as RNAZ and TSBX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BCLI's gross margin of N/A stands against RNAZ's N/A and TSBX's N/A. Such benchmarking helps identify whether Brainstorm Cell Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Financials
FY2025Q1
YoY:
+24.86%
-3.09M
Operating Profit
FY2025Q1
YoY:
-15.79%
-2.86M
Net Income after Tax
FY2025Q1
YoY:
-43.04%
-0.45
EPS - Diluted
FY2024Q4
YoY:
-68.10%
-1.05M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。